Valuation: ARS Pharmaceuticals, Inc.

Market Cap 804M 706M 651M 602M 1.14B 77.02B 1.16B 7.83B 3.04B 37.69B 3.02B 2.95B 131B P/E 2026 *
-4.59x
P/E 2027 * -9.05x
Enterprise Value 804M 706M 651M 602M 1.14B 77.02B 1.16B 7.83B 3.04B 37.69B 3.02B 2.95B 131B EV / Sales 2026 *
5.67x
EV / Sales 2027 * 3.16x
Free-Float
83.79%
Yield 2026 *
-
Yield 2027 * -
1 day-1.10%
1 week+1.12%
Current month+1.12%
1 month-5.37%
3 months-0.61%
6 months-27.03%
Current year-30.47%
1 week 7.49
Extreme 7.49
8.66
1 month 7.49
Extreme 7.49
10.87
Current year 7.03
Extreme 7.03
13.15
1 year 6.66
Extreme 6.66
18.63
3 years 2.55
Extreme 2.55
18.9
5 years 2.55
Extreme 2.55
18.9
10 years 2.55
Extreme 2.55
18.9
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 05/08/2015
Chief Executive Officer 53 07/07/2026
Chief Tech/Sci/R&D Officer 57 01/09/2018
Director TitleAgeSince
Chairman 56 08/11/2022
Director/Board Member 55 01/08/2021
Director/Board Member 56 01/07/2017
Date Insider Type Main position Quantity % Market Cap.
07-01Free

Chief Executive Officer

898,456 0.9048%
06-24Free

Director

30,000 0.0302%
06-24Free

Director

30,000 0.0302%
Change 5-day change 1-year change 3-year change Capi.($)
-1.10%+1.12%-52.60%+32.14% 813M
-0.24%+4.98%+2.69%+9.14% 49.74B
-0.36%+1.33%+417.51%+619.10% 40.49B
-2.29%+5.93%+25.27%+59.26% 34.35B
-2.13%+5.47%+25.45%-6.01% 34.75B
-0.79%+2.02%+3.83%+36.42% 26.98B
+3.82%+3.92% - - 16.58B
-2.62%+0.45%+66.82%+125.87% 15.6B
-2.17%+6.52%+102.15%+102.15% 14.27B
-2.70%-2.19%+11.25%+18.19% 13.76B
Average -1.06%+3.81%+66.93%+110.70% 24.73B
Weighted average by Cap. -1.00%+4.36%+93.20%+138.80%

Financials

2026 *2027 *
Net sales 142M 124M 115M 106M 201M 13.57B 205M 1.38B 536M 6.64B 532M 521M 23.06B 255M 223M 206M 191M 361M 24.39B 369M 2.48B 963M 11.94B 957M 936M 41.43B
Net income -176M -155M -143M -132M -250M -16.87B -255M -1.72B -667M -8.26B -662M -647M -28.66B -90.88M -79.71M -73.59M -68M -129M -8.7B -131M -885M -344M -4.26B -341M -334M -14.78B
Net Debt - -
Logo ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.
Employees
157
Date Price Change Volume
08/07/26 $8.100 -1.10% 2,036,543
07/07/26 $8.190 -1.68% 1,235,305
06/07/26 $8.330 -2.69% 1,124,311
02/07/26 $8.560 +7.81% 1,796,362
01/07/26 $7.940 -0.87% 1,148,695
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
8.190USD
Average target price
29.25USD
Spread / Average Target
+257.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRY Stock